Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.86 -1.66 (-3.42%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
76 77 Next >
3 Hidden Stock Gems That Wall Street Is Overlooking
If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three. 
Via InvestorPlace
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
What the Options Market Tells Us About Bristol-Myers Squibb
Via Benzinga
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice. 
Via InvestorPlace
What the Options Market Tells Us About Bristol-Myers Squibb
Via Benzinga
Bristol-Myers Squibb Stock Price Forecast: Is The Downtrend Finally Over?
Technical analysis suggests short-term support at $39.90; potential recovery to $56. 
Via Talk Markets
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
Is Bristol Myers Squibb Stock a Buy?
Does Bristol Myers have the potential to be a market-beating stock? 
Via The Motley Fool
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
Via Benzinga
You’ve Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.
Pharmaceutical stocks can be considered risky, but when their trials get approved by FDA, the stock can go to the moon. 
Via InvestorPlace
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer. 
Via Benzinga
7 Dividend Stocks to Buy Now: June 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
S&P 500 Earnings Dashboard 24Q1 - Saturday, June 22
Of the 498 companies in the S&P 500 that have reported earnings to date for 24Q1, 78.7% reported above analyst expectations. This compares to a long-term average of 66%. 
Via Talk Markets
Topics Stocks
3 No-Brainer Stocks to Buy for Under $100 Right Now
You won't need much money to start investing in these great stocks. 
Via The Motley Fool
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields. 
Via The Motley Fool
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
From Bristol Myers Squibb
Via Business Wire
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
From Bristol Myers Squibb
Via Business Wire
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
From Bristol Myers Squibb
Via Business Wire
3 Warren Buffett Stocks to Buy Now: June 2024
If you have a long-term view of the market, it’s a good time to look for some Warren Buffett stocks to buy now. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
From Bristol Myers Squibb
Via Business Wire
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
These two pharma stocks are beloved by income investors. 
Via The Motley Fool
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback